Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

Core Insights - Enliven Therapeutics, Inc. announced the presentation of data from its ENABLE Phase 1a/1b clinical trial of ELVN-001 at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting [1] - The presentation will include both an oral and a poster session, showcasing the company's focus on chronic myeloid leukemia treatment [2] Company Overview - Enliven Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of small molecule therapeutics aimed at improving patient survival and overall well-being [3] - The company employs a precision oncology approach to address unmet medical needs, leveraging insights into clinically validated biological targets and innovative chemistry [3]